Assessing and Influencing Prognosis in Hepatocellular Carcinoma

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a challenging disease to deal with. Patients are often diagnosed in advanced stages and, in these patients, therapeutic options are often limited to disease control rather than curative treatment. However, this group of patients is heterogeneous; hence, there is a need for better prognostication. First of all, this could allow medical professionals to provide better information to patients and this could support a better selection of the appropriate treatment for every single patient.

This evolution towards precision medicine is developing rapidly in all fields of medicine, as it is in HCC. This Special Issue will be entitled “Assessing and Influencing Prognosis in Hepatocellular Carcinoma” and will cover clinical and translational aspects. Indeed, this issue should provide a comprehensive overview of established or potential prognostic biomarkers in HCC. Review manuscripts of original scientific content will be included. This will be combined with manuscripts dealing with more fundamental aspects that can shed light on the heterogeneity of disease progression and could provide mechanistic clues as regards disease progression.

Prof. Dr. Xavier Verhelst
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.